Journal of the National Comprehensive Cancer Network

Article	Citations
HSR22-175: Impact of ‘Choosing Wisely’ on Unnecessary Staging Imaging in Patients With Early Stage Breast Cancer: A Seer-Medicare Analysis	958
HSR22-122: Racial Disparities in Breast Cancer-Specific Survival Among Women Aged 40 Years or Younger in the United States	874
QIM22-193: Development and Implementation of a Scheduling Tool to Improve Patient Access to Outpatient Care in an Academic Cancer Center	759
CLO22-063: Study on Correlation Between Serum CA 19-9 and Colorectal Carcinoma With Normal CEA	611
NCCN News	603
Abstracts From the NCCN 2022 Annual Conference	430
HSR22-123: Breaking Cost Barriers in Treatment With Biosimilars–Improvement in Affordability of Trastuzumab Against HER2 Positive Breast Cancer Amongst Indian Women	397
HSR22-138: Oncologist’s Perceptions on Immune Checkpoint Inhibitor Therapies for Non-Small Cell Lung Cancer	342
CLO22-045: Gastrointestinal Safety Profile of Sonic Hedgehog Inhibitors in Basal Cell Carcinoma (BCC): A Systematic Review and Meta-analysis	323
NCCN News	273
Metastasis and Mortality in Men With Low- and Intermediate-Risk Prostate Cancer on Active Surveillance	273
Cancer-Associated Venous Thromboembolic Disease, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology	261
Evaluation of NCI-Designated Cancer Center and Comprehensive Cancer Center Survivorship-Focused Websites: Information Provided and Accessibility	243
NCCN News	237
NCCN News	233
CLO22-060: > 3 Courses of Neo-Adjuvant Chemotherapy (NACT) May Affect Outcomes of Advanced Ovarian Serous Adenocarcinoma Patients	230
YIA22-008: Identification of Biomarkers That Predict Responses to Immunotherapy in Merkel Cell Carcinoma	225
Application of the Socioecological Model to Regional Clinical Trials: A Paradigm-Shift to Advance Scientific Discovery and Prognostic Modeling	224
CGE22-101: Dynamically Accumulating Homologous Recombination Deficiency (HRD) Status Served as an Important Prognosis Factor in High-Grade Serous Ovarian Cancer	214
Letter to the Editor Re: Influence of Food With Different Fat Concentrations on Alectinib Exposure: A Randomized Crossover Pharmacokinetic Trial	210
Highlights of the NCCN Oncology Research Program	205
Local Recurrence and Disease-Free Survival After Transanal Total Mesorectal Excision: Results From the International TaTME Registry	187
Effect of Yoga and Mediational Influence of Fatigue on Walking, Physical Activity, and Quality of Life Among Cancer Survivors	150
Statin Use During Concurrent Chemoradiotherapy for Advanced Nasopharyngeal Cancer	137
Keynote Session: Strategies for Prevention and Control of HPV-Associated Cancers	127

CLO22-052: A Tale of Two Schedules: A Study of the Efficacy and Toxicity Outcomes of Extended Durvalumab Dosing in Patients with Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)	126
Management of Recurrent or Metastatic Cervical Cancer	117
Representation and Outcomes of Older Adults in Practice-Changing Oncology Trials in the Era of Novel Therapies: A Guideline Appraisal	114
Localized Gastroesophageal Cancers: Can We Shift the Current Treatment Paradigms?	110
HSR22-174: Are We ‘Choosing Wisely’? A Case of Unnecessary Staging Imaging in Older Patients With Prostate Cancer	107
CLO22-073: Familial Nevoid Basal Cell Carcinoma Syndrome (NBCCS) Associated to Novel PTCH1 Mutation c.1067 + 2T>C of Paternal Origin in Somatic Mosaicism With Marked Phenotypic Variation in the Chi	100
QIM22-191: Expansion of Tobacco Cessation Treatment Within the Stanford Cancer Institute: 6-Month and 24-Month Outcomes	94
HSR22-154: Treatment Patterns Following Osimertinib Discontinuation in Patients With EGFR Mutated Metastatic NSCLC	85
CLO22-069: Radiation Induced Lymphopenia (RAILs on Time Saves Nine!) In Carcinoma Esophagus!	85
My Report Card	85
Cutaneous Melanoma: Management of Melanoma Brain Metastases and Molecular Testing	84
Highlights of the NCCN Oncology Research Program	80
HSR22-171: Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Older Versus Younger Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated in a Pha	80
PCL22-187: Functional Role of TREM2 in NASH and HCC Development	72
QIM23-132: Do EHR-Embedded Clinical Decision Support Tools Reduce Variation in Care? A Pre and Post-Implementation Comparison of Regimen Ordering Variation at a Multi-Site Community Cancer Clinic	70
Highlights of the NCCN Oncology Research Program	70
Mutational Landscape in Myeloproliferative Neoplasms: Implications on Prognosis and Clinical Management	68
HSR22-130: A Retrospective Cohort Study of Selpercatinib-Treated Patients With Advanced/Metastatic Non-Small Cell Lung Cancer: Preliminary Findings From a Real-World Database in the United States	61
CGE22-103: Identifying Patients at Risk for Hereditary Myeloid Malignancy Syndromes Using a Self-Administered Questionnaire as an Initial Screening Tool: A Single Center Experience	60
Treatment of Locally Advanced/Metastatic Colorectal Cancer	56
Representation of Sexual and Gender Minority People in Patient Nondiscrimination Policies of Cancer Centers in the United States	55
Patient-Reported Symptom Complexity and Acute Care Utilization Among Patients With Cancer: A Population-Based Study Using a Novel Symptom Complexity Algorithm and Observational Data	49
Treatment Updates in Acute Myeloid Leukemia	48
Comorbidities, Rather Than Older Age, Are Strongly Associated With Higher Utilization of Healthcare in Colorectal Cancer Survivors	46
CLO22-032: Effect of COVID-19 Causing Treatment Delay in Cancer Patients Receiving Immune Checkpoint Inhibitors	43
I’m Getting Better at This!	42
NCCN News	42
NCCN News	42
Outcomes in Nonmetastatic Hormone Receptor–Positive HER2-Negative Pure Mucinous Breast Cancer: A Multicenter Cohort Study	41
Integrating Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Practical Evidence-Based Considerations	41
Rates of Menstrual History-Taking and Counseling With Anticancer Treatments Are Low: People Who Menstruate Deserve Gender-Specific Cancer Care	41
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024	40
A Positive Psychology Intervention in Allogeneic Hematopoietic Stem Cell Transplantation Survivors (PATH): A Pilot Randomized Clinical Trial	40
Pharmacogenetics in the Treatment and Supportive Care of Patients With Cancer	40
Highlights of the NCCN Oncology Research Program	38
Management of Patients With Aggressive Nonmelanoma Skin Cancers	38
CLO22-033: Clinicopathologic and Sociodemographic Factors Associated With Late Relapse Triple Negative Breast Cancer	36
Maneuvering the Complex Web of Treatment Options for Relapsed/Refractory Multiple Myeloma	36
CGE22-095: CCND1 Amplification in Pancreatic Ductal and Ampullary Adenocarcinoma and Its Impact on Patients’ Survival: A Single Centre Observational Study	36
QIM22-189: Harnessing Pathway Power: Development of a Clinical Pathway Program in a Comprehensive Cancer Center for Improved EOL Care and Beyond	36
CLO22-092: Prostate Cancer With Osteolytic Bone Metastasis on 68GaPSMA PET/CT: Staging and Response Assessment	36
CLO22-061: c-MET Alteration in Patients With Metastasized Colorectal Carcinoma – An Evaluation of Methods of Detection, Clinical Impact and Discussion of c-MET as Potential Therapeutic Target	35
HSR22-151: Access to Care and Health Care Quality Metrics in Urban Versus Rural Patients With Advanced Genitourinary Cancers	33
QIM22-201: Experiences With Cancer Diagnosis and Treatment in Rural Nebraska: Qualitative Focus Group Analysis	32
QIM22-205: Implementation of a Comprehensive Pre-Habilitation Program for Patients Undergoing Radical Cystectomy	32
CLO22-058: Sex Differences in Pain Relief From Medical Cannabis in Patients With Cancer: Results From the Quebec Cannabis Registry	32
HSR22-135: Telemedicine for Cranial Radiosurgery Patients in a Rural US Population: Patterns and Predictors of Patient Utilization	32
PCL22-186: A Potential Biomarker for Radiosensitivity of Squamous Cell Carcinomas in the Head and Neck	31
A Survey of the National Comprehensive Cancer Network on Approaches Toward Addressing Patients’ Transportation Insecurity	30
Highlights of the NCCN Oncology Research Program	30

CLO22-034: Subtotal Glossectomy. Functional Outcomes After Compartmental Tongue Resection and Reconstruction With Pectoralis Major Myocutaneous Flap	29
BIO22-026: Chemotherapy and Immunotherapy Infusion Reaction Documentation Standardization	29
Association Between Pretreatment Skeletal Muscle and Outcomes After CAR T-Cell Therapy	28
EPR22-109: Cancer Incidence in Immunocompromised Patients	28
TIP24-198: A Multi-Center Phase I Trial of Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Refractory Gastric Cancer Patients	28
QIM24-192: Place of Death From Cancer in Episodic Value Based Care Models in a Community Oncology Network	26
HSR24-127: Rectal Cancer Disparities in Age and Overall Survival Among American Indian and Alaska Native Vs Non-Hispanic White Populations	24
QIM24-190: A Safety Net System for Significant Diagnostic Imaging Actionable Findings at a Comprehensive Cancer Care Center	24
YIA24-002: Patients’ Perspectives on Being Treated by Multiple Care Teams for Autologous Transplant/CAR-T Eligible Lymphoma and Multiple Myeloma	24
CLO24-072: Length of Hospital Stay, Unplanned Readmission and Mortality for Patients Treated With Partial Nephrectomy or Radical Nephrectomy for Stage I and II Kidney Tumors	24
CLO24-055: Outcomes With Sacituzumab Govitecan in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis	23
YIA24-005: MAIT Cells are Reduced in Anorectal Mucosal Melanomas Compared to Cutaneous Melanoma GI Metastases	23
CLO24-084: Myeloid Sarcoma in a Patient With Marfan Syndrome	22
Patients With cT1N0M0 Oral Squamous Cell Carcinoma Benefit From Elective Neck Dissection: A SEER-Based Study	22
Intravenous Patient-Controlled Analgesia Versus Oral Opioid to Maintain Analgesia for Severe Cancer Pain: A Randomized Phase II Trial	21
Highlights of the NCCN Oncology Research Program	21
Updates in the Treatment of Patients With Colorectal Cancer	20
Highlights of the NCCN Oncology Research Program	20
Dying in the Queue and Where Is My Nurse?	20
Privacy on the Road to Personalized Medicine	20
Relapsed/Refractory CLL/SLL: Overcoming Resistance to Covalent BTKi and/or BCL2 Inhibitors	19
Fecal Immunochemical Testing in Patients With Low-Risk Symptoms of Colorectal Cancer: A Diagnostic Accuracy Study	18
Response to Dabrafenib Plus Trametinib in a Patient With an Uncommon Activating BRAF Mutation: A First in Non–Small Cell Lung Cancer	18
Updates to the Management of HR-Positive, HER2-Negative Breast Cancer	18
CLO23-052: Risk Factors and Prognosis of Stroke in Gynecologic Cancer	17
NCCN News	17
HSR23-090: Racial Differences in Outcomes of Osimertinib in Patients With EGFR-Positive Non–Small Cell Lung Cancer in a Real World US Population	17
Optimizing Treatment Approaches for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	17
EPR23-085: Prevalence of Substance Use in Cancer Patients at a 5-Year Difference: A Cross-Sectional Study From Nationally Representative Population	17
Management of Patients With Advanced Melanoma	17
CLO23-029: An APP-Run Lymphadenopathy Clinic: The Cleveland Clinic Experience	16
CLO23-035: Expression of PD-L1 Through Evolution Phase From Pre-Invasive to Invasive Lung Adenocarcinoma	16
CLO23-045: A Prospective Interventional Study to Assess the Response of Systemic Chemotherapy in Aggressive, Recurrent Giant Cell Tumor	16
CLO23-057: The Influence of Operability Status on Outcomes in Patients With T4a Larynx Cancer: An Institutional Experience	16
EPR23-087: Perceived Risk and Uptake of Healthy Lifestyle Behaviors for Breast Cancer Prevention Among High-Risk Women	16
EPR23-086: Knowing the Lymphomas of the Legal Amazon: How Do They Differ?	16
HSR23-092: Real-World Analysis Examining Cost of Early Disease Progression Among Patients With Epidermal Growth Factor Receptor Mutated Metastatic Non–Small Cell Lung Cancer	15
HSR23-103: Pancreatic Cancer: The Impact of Early Connectivity and Coordination of Care on Retention and Time to Treat	15
CLO23-053: Update From the Dedalo Protocol: An Integrated Approach to MRD in CLL Patients Receiving Venetoclax Plus Rituximab	15
HSR23-114: Clinical Characteristics and Outcomes of US Extensive Stage Small Cell Lung Cancer (ES-SCLC) Patients Not Receiving Guideline Preferred Regimens	15
HSR23-095: Outcomes of Patients With Pancreatic Cancer Undergoing Duodenal Stent Placement: A Population-Based Study	15
HSR23-117: First-Line (1L) Systemic Therapy in Patients (pts) With Advanced Non–Small Cell Lung Cancer (aNSCLC) at Community Settings in the United States (US)	15
HSR23-123: Conventional Hydration Versus Short Hydration for Reducing Chemotherapy Induced Nephrotoxicity (CIN) Among Adult Esophageal Cancer Patients at Uganda Cancer Institute, Mbarara – Uganda: An	14
QIM23-138: Using the Electronic Health Record (EHR) to Capture Structured Oncology Data in Real-Time at the Point-of-Care: A Mayo Clinic Comprehensive Cancer Center (MCCCC) Pilot Study	14
CLO23-043: Optimal Interval Between Immune Therapy and Targeted Therapy With Sotorasib in Patients With KRAS G12C Mutant Non–Small Cell Lung Cancer	14
QIM23-137: Improving Hematology-Oncology Education in Internal Medicine Residency—A Single Institution Quality Improvement Project	14
EPR23-078: Analyzing Trends in the Incidence and Mortality of Esophageal Cancer in the United States: A 15-Year Population-Based Study	14
BIO23-021: Digital Multidisciplinary Meetings Enable Regional Specialist Oncology Treatment	14
QIM23-126: Positive Quality Intervention in Action: Implementation and Value in Practice	14
BPI23-013: Comparison of Modified Patient-Reported Paper G8 and EPIC G4 + 4 With Clinician-Reported Standard G8 to Screen Frailty in Elderly Patients With Cancer	14
HSR23-120: Real-World Observations Show Beneficial Outcomes in Patients With NSCLC Treated With Pembrolizumab for More Than 2 Years	14
EPR23-083: Non-Squamous, Metastatic Non–Small Cell Lung Cancer: Retrospective c-Met Overexpression Testing, Patient Characteristics, and Treatment Patterns	14
HSR23-096: COVID-19 Impact and Psychosocial Well-Being Among Adults Living With Cancer: A Longitudinal Analysis	13
The NCCN 2021 Virtual Congress: Hematologic Malignancies	13
Letter to the Editor: Re: Reimagining Cancer Staging in the Era of Evolutionary Oncology	13
HSR23-101: Characteristics and Outcomes of Patients Treated With Selpercatinib in the Real-World: A Retrospective Study Using US Claims Databases	13
BIO23-023: Supporting the Capture of Structured Data for Patients With Cancer Using Cancer-Specific Note Templates	13
EHR-Integrated Patient-Reported Outcomes in Ambulatory Oncology: A Critical Opportunity for Timely and Targeted Palliative Care	13
Treatment Trends and Clinical Outcomes of Left-Sided RAS/RAF Wild-Type Metastatic Colorectal Cancer in the United States	13
CLO23-061: Evaluation of Adding Neck Dissection to N0 Head and Neck Cancer Patients	13
QIM23-130: Committing to Resiliency: Transforming Burnout to Resilience at a National Cancer Institute (NCI) Comprehensive Cancer Center	13
Highlights of the NCCN Oncology Research Program	13
Evaluation of Scores to Reflect Toxicity Impact on Quality of Life of Patients With Platinum-Resistant Ovarian Cancer: AURELIA Substudy	12
Highlights of the NCCN Oncology Research Program	12
Management of Metastatic Prostate Cancer	12
Giving Thanks	12
NCCN News	12
Association of Polypharmacy and Potentially Inappropriate Medications With Frailty Among Older Adults With Blood Cancers	11
Response of a Novel KANK1::ALK Fusion to Alectinib in an Advanced Lung Adenocarcinoma: A Case Report	11
Risk of Cancer-Specific Death for Patients Diagnosed With Neuroendocrine Tumors: A Population-Based Analysis	11
Cancer Rehabilitation: Impact on Breast Cancer Survivors’ Work Ability and Health-Related Quality of Life	11
Rechallenge With Switching Immune Checkpoint Inhibitors Following Autoimmune Myocarditis in a Patient With Lynch Syndrome	11
A Case of Lung Adenocarcinoma Response to Alectinib Harboring a Rare EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK	11
Visa Constraints and Career Choices for Oncologists	11
Involving Family and Social Support Systems in Tobacco Cessation Treatment for Patients With Cancer	11
Advances in the Management of Classical Hodgkin Lymphoma	11
HSR22-131: Incremental Health Care Costs of Anxiety and Depression Among Medicare Beneficiaries With Cancer	11
EPR24-111: The Clinical Effect of a Community-Based Genetic Testing Program	10
HSR24-131: Patient Experiences and Perceptions of Biomarker Testing in AML and CML: A Qualitative Analysis	10
Mesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology	10

HSR24-128: Real-World Treatment Patterns and Effectiveness of Selpercatinib in Patients With Locally Advanced/Metastatic Non–Small Cell Lung Cancer in the US	10
HSR24-152: Patient-Reported Outcome (PRO) Data in Oncology NDAs Approved by the FDA (2018–2021): A Review of Criticism and Concerns in Comments From Regulators	10
CLO24-065: Administration of Goserelin at Alternative Anatomical Sites in Premenopausal Breast Cancer	10
HSR24-163: Comparative Assessment of Social Determinants of Health in Community and Academic Hospitals for Patients Diagnosed With Hepatocellular Carcinoma	10
CLO24-079: Results From Phase 3 Trial of Imetelstat, a First-in-Class Telomerase Inhibitor, in Patients With Red Blood Cell Transfusion Dependent (RBC-TD) Non-del(5q) Lower-Risk Myelodysplastic Syndro	10
CLO24-059: The Impact of Proton Pump Inhibitors on Palbociclib in Advanced Breast Cancer Patients: A Systematic Review and Meta-Analysis	9
EPR24-098: Epidemiological and Survival Analysis of Hemangiosarcoma in the Last Twenty Years	9
EPR24-119: Development of Heart Failure Following Anthracycline Exposure in Survivors of Adolescent and Young Adult Cancer in an Integrated Healthcare System	9
CLO24-077: Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma in the Era of Immunotherapy: An Analysis of the National Cancer Database (NCDB)	9
QIM24-179: Instituting Quality Improvement Processes With Periprocedural Heparin Infusions at a Major Cancer Center Utilizing a Failure Mode and Effects Analysis	9
HSR24-159: Relationship Between Durable Transfusion Independence (TI) and Survival Outcomes in Patients (Pts) With Lower-Risk Myelodysplastic Syndrome (LR-MDS): An Analysis From US Health Insurance Cl	9
CLO24-071: A Propensity Matched Survival Analysis Comparing Partial Versus Radical Nephrectomy in Patients with Metastatic Renal Cell Carcinoma: A National Cancer Database Study	9
HSR24-169: Autonomic Symptoms May Suggest Paraneoplastic Neurological Syndromes in Small Cell Lung Cancer	9
EPR24-113: The Role of Social Determinants of Health in Gastrointestinal Cancer Outcomes in the United States Context: A Systematic Review	9
EPR24-108: The Effect of Exercise on Cardiotoxicity in Women With Breast Cancer Receiving Anthracycline-Based Chemotherapy: A Systematic Review and Meta-Analysis	9
HSR24-153: Real-World Clinical Outcomes of First-Line Therapies and Treatment Regimens for BRAF-Mutant Advanced/Metastatic Melanoma: Retrospective Observational Study	9
HSR24-141: Personalizing the Patient Experience: Understanding the Emotional State and Learning Preferences of Pancreatic Cancer Patients Receiving Multidisciplinary Care	8
CLO24-063: Red Cell Distribution Width and Putative Severity Markers as Predictors of Short-Term Critical Illness in Hospitalized Cancer Patients	8
CLO24-082: A National Cancer Data Base (NCDB) Analysis of Prognostic Factors in Metastatic Triple-Negative Breast Cancer (TNBC)	8
PCO24-175: Immune Cell Dynamics After Radiotherapy for Oligometastatic Prostate Cancer	8
CRE24-049: Extrapulmonary Small Cell Carcinoma of Gallbladder Presenting as Acute Cholecystitis	8
HSR24-144: Does Immunotherapy Work in Patients With Poor Performance Status?	8
CRE24-035: Pembrolizumab-Induced Hemophagocytic Lymphohistiocytosis in a Patient With Breast Cancer: A Case Report and Systematic Review of the Literature	8
TIP24-199: Rhenium (Re-186) Obisbemeda {Re-186-Nanoliposome (186RNL)} in Leptomeningeal Metastases [LM] Phase 1/2A Dose Escalation Trial: Update of Initial Safety and Feasibility Through Cohorts 1–4	8
EPR24-099: Clinical and Epidemiological Characterization of the Oncologic Population in a Third Level Hospital in Northeastern Mexico	8
CLO24-060: Organomegalies as a Predictive Indicator of Leukemia Cutis in the Patients With Acute Myeloid Leukemia	8
YIA24-004: Liquid Biomarkers of Response to Radium-223 in Metastatic Prostate Cancer	8
Mode of Detection of Second Breast Cancers in Patients Undergoing Surveillance After Treatment of Ductal Carcinoma in Situ	7
Cost-Effectiveness Analyses in AML: What Have We Learned, How Should This Impact Patient Care, and What Needs to Be Done in the Future?	7
Frailty in Long-Term Prostate Cancer Survivors and Its Association With Quality of Life and Emotional Health	7
An Unexpected Diagnosis Uncovered by Quantitative Molecular Findings: A Case Report	7
Pancreatic Cancer Progression in a Patient With Lynch Syndrome Receiving Immunotherapy: A Cautionary Tale	7
Recommendations for Managing Adults With Histiocytic Neoplasms: New NCCN Guidelines	7
Erratum	7
Highlights of the NCCN Oncology Research Program	7
NCCN News	7
Metastatic Parotid Gland Carcinoma With ERBB2 Amplification With Complete Response to Fam‐Trastuzumab Deruxtecan	7
Dermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology	7
Thank You To 2024 JNCCN Reviewers	7
Proportion of Gleason Score ≥8 Prostate Cancer on Biopsy and Tumor Aggressiveness in Matched Cohorts of East Asian and Non-East Asian Men	6
Adjuvant Hormone Therapy–Related Hot Flashes Predict Treatment Discontinuation and Worse Breast Cancer Prognosis	6
Prognosis After Pathologic Complete Response to Neoadjuvant Therapy in Early-Stage Breast Cancer: A Population-Based Study	6
The Oncologist Outside the Exam Room	6
Oncology Survivorship Care Clinics: Design and Implementation of Survivorship Care Delivery Systems at NCCN Member Institutions	6
HER2 Targeting in Esophagogastric Cancer: Redefining the Landscape and Breaking Barriers	6
Understanding Disparities: A Case Illustrative of the Struggles Facing Transgender and Gender Diverse Patients With Cancer	6
Is Biannual Surveillance for Pancreatic Cancer Sufficient in Individuals With Genetic Syndromes or Familial Pancreatic Cancer?	6
Lobbying in US Health Care—Lessons From the Field of Oncology	6
Prevalence of Anemia and Compliance With NCCN Guidelines for Evaluation and Treatment of Anemia in Patients With Gynecologic Cancer	6
Highlights of the NCCN Oncology Research Program	6
Empowering Care Teams: Redefining Message Management to Enhance Care Delivery and Alleviate Oncologist Burnout	6
HSR22-145: Pembrolizumab Plus Chemotherapy for First-Line Treatment of Advanced Triple-Negative Breast Cancer – A Network Meta-Analysis	6
Pilot Trial of Streamlined Genetic Education and Traceback Genetic Testing in Prostate Cancer Survivors	6
Gastroesophageal Adenocarcinomas With Defective Mismatch Repair: Current Knowledge and Clinical Management	6
Unveiling Discrepant and Rare Dihydropyrimidine Dehydrogenase (DPYD) Results Using an In-House Genotyping Test: A Case Series	6
NCCN News	6
A New Administration and JNCCN	6
Combination Therapy of Physical Activity and Dexamethasone for Cancer-Related Fatigue: A Phase II Randomized Double-Blind Controlled Trial	6
Patient-Centered Decision-Making in Metastatic Breast Cancer Care Delivery: A Call to Action	6
Update on Guidelines for the Prevention of Cancer-Associated Thrombosis	6
Exceptional Response to Erdafitinib in FGFR2-Mutated Metastatic Pancreatic Ductal Adenocarcinoma	6
Toward Precision Pancreatic Cancer Care	6
QIM25-231: Implementation of an Emergent Response System in an Urban Oncology Infusion Unit: A Quality Improvement Initiative	5
HSR22-172: Immunogenicity of ChAdOx1-nCoV-19 Vaccination for Solid Cancer Patients, Prospective Observational Multicenter Study - Preliminary Report	5
Racial and Ethnic Disparities in the Time to Ovarian Cancer Surgery in Patients at an Integrated Health Care Delivery System	5
Implementation of ePROs Into Multidisciplinary Tumor Board Discussions for Patients With Pancreatic Cancer: The INSPIRE Intervention	5
Patient-Reported Outcome Measures in Chemotherapy-Induced Peripheral Neurotoxicity: Defining Minimal and Clinically Important Changes	5
YIA25-002: SyMPLER Palliative Care: Symptom Monitoring Program Linked to Electronic Referrals to Palliative Care	5
TIP25-241: Utilizing Augmented Reality as an Adjunct for Smoking Cessation: Trial in Progress	5
QIM25-234: Models and Outcomes of Multidisciplinary Clinics in Lung Cancer	5
QIM25-235: Exocrine Pancreatic Insufficiency (EPI) in Pancreatic Cancer Patients: Increasing Awareness and Screening	5
CGE25-112: Analyzing the Prognostic Significance of Common Mutations in Pancreatic Cancer (PC) via Next Generation Sequencing (NGS)	5
Hemithyroidectomy Versus Total Thyroidectomy for Sporadic Medullary Thyroid Cancer: A Chinese Nationwide Large-Scale Cohort Study	5
Metastatic Spiradenocarcinoma Managed With PD-1 Inhibition	5
Letter to the Editor: Enhancing the Readability of Online Patient-Facing Content Using AI Chatbots	5
Improving Health Equity and Reducing Disparities in Pediatric and Adolescent/Young Adult Oncology: In Support of Clinical Practice Guidelines	5
Androgen Deprivation Therapy and Risk of Cardiovascular Disease in Patients With Prostate Cancer Based on Existence of Cardiovascular Risk	5
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023	5
QIM25-218: Improving Quality Outcomes Through a Hospitalist-Driven Malignant Hematology Service	5
BPI25-019: Empirical Study to Estimate Real World Impact of Delay in EGFR Testing on Healthcare Resource Utilization and Cost Burden Among Early-Stage NSCLC Patients	5
PCO25-211: HIF-1α Inhibitor ACF Synergizes With PARP Inhibitors Through the Exacerbation of Transcription-Replication Conflicts in Ovarian Cancer	5
Immune-Related Adverse Events Among COVID-19–Vaccinated Patients With Cancer Receiving Immune Checkpoint Blockade	5
Early Antibiotic Discontinuation or De-escalation in High-Risk Patients With AML With Febrile Neutropenia and Prolonged Neutropenia	5
Achieving Adherence With NCCN Guidelines for Nonmelanoma Skin Cancer Regarding Peripheral and Deep En Face Margin Assessment (PDEMA)	5
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021	5
Social Determinants of Health and Racial Disparities in Cardiac Events in Breast Cancer	5
CGE25-109: Mapping Common Oncogene Protein-Protein Interactions to Discover New Targets in HRD-Negative Ovarian Cancer	5
BPI25-016: Real-World Outcomes of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Insights From a Single Center in the Deep South	5
QIM25-232: Extracellular Vesicles Evade the Antiangiogenic Effect of Bevacizumab in Ovarian Cancer	5
BIO25-023: Patient Perceptions of Artificial Intelligence in Healthcare: Findings from the Cancer Experience Registry	4
TIP25-242: The PREDICT II Registry: A Prospective Study to Evaluate the Clinical Utility of a 7-Gene Predictive Biosignature on Treatment Decisions in Patients With Ductal Carcinoma In Situ	4
BPI25-005: Molecular Biomarker Testing Patterns and Turn-Around Time in US Patients With Advanced Non-Small Cell Lung Cancer	4
HSR25-181: Assessment of Content Validity of the Functional Assessment of Cancer Therapy – Cutaneous T-Cell Lymphoma (FACT-CTCL)	4
BIO25-027: Addressing Early Diagnosis Challenges: Utilizing C the Signs Clinical Decision Support Platform for Pancreatic Cancer Risk Assessment	4
EPR25-129: Predictors of Brain, Bone, and Liver Metastasis in Lung Cancer: A Logistic Regression Analysis	4